Relmada Therapeutics, Inc. (RLMD) stock
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.01−0.60 (-16.62%)
Close on Nov 17, 2026Market cap $321.08MP/E –Yield –
Relmada Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Relmada Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$65.13M. For fiscal 2025 it was -$59.10M. The highest annual figure on record is -$3.16M in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$59.10M | – |
| FY2024 | Dec 31, 2024 | -$83.89M | – |
| FY2023 | Dec 31, 2023 | -$103.70M | – |
| FY2022 | Dec 31, 2022 | -$161.25M | – |
| FY2021 | Dec 31, 2021 | -$125.70M | – |
| FY2019 | Jun 30, 2019 | -$12.73M | – |
| FY2018 | Jun 30, 2018 | -$6.92M | – |
| FY2017 | Jun 30, 2017 | -$7.22M | – |
| FY2016 | Jun 30, 2016 | -$16.22M | – |
| FY2013 | Dec 31, 2013 | -$6.77M | – |
| FY2012 | Dec 31, 2012 | -$3.16M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$15.01M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$19.46M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$20.33M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$10.33M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$10.22M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$18.22M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$19.08M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$23.01M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$18.82M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$22.99M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$26.83M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$22.69M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$26.03M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$28.15M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$38.70M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$38.30M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$34.18M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$42.65M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$26.46M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$22.41M | – |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$4.14M | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -$2.70M | – |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$3.48M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -$2.41M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$1.93M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$2.55M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.46M | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$980.86K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$1.78M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$2.28M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$1.54M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$1.62M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$3.10M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$2.75M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$5.72M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$4.63M | – |
| Q4 FY2013CQ4 2013 | Dec 31, 2013 | -$5.06M | – |
| Q3 FY2013CQ3 2013 | Sep 30, 2013 | -$481.84K | – |
See a number that looks wrong?